Image de couverture de livre

Diagnosis and non‐invasive assessment of MASLD in type 2 diabetes and obesity

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Wah‐Kheong Chan, Salvatore Petta, Mazen Noureddin, George Boon Bee Goh, Vincent Wai‐Sun Wong
Format:	Artículo Open Access
Publié:	Wiley 2024
Sujets:	Alimentary Pharmacology & Therapeutics
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Letter: Impact of Nonalcoholic Fatty Liver Disease on the Survival of People Living With HIV
par: Rong‐Xiang Ng, et autres
Publié: (2025)

Editorial: Does Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ) With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease?
par: C. C. Mark Cheah, et autres
Publié: (2025)

Editorial: Combination Therapies for MASH : A Step Forward or More Complexity?
par: Xiao‐Dong Zhou, et autres
Publié: (2025)

A Prospective Study on the Prevalence of MASLD in Patients With Type 2 Diabetes and Hyperferritinaemia
par: Maral Amangurbanova, et autres
Publié: (2024)

Letter: Using non‐invasive fibrosis tests and emerging diagnostics to enhance the accuracy of liver fibrosis staging in MASLD patients
par: Wenjun Meng, et autres
Publié: (2024)

Editorial: Accelerometers to Quantify Physical Activity in MASLD—Impact on Clinical Outcomes
par: Vincent L. Chen
Publié: (2025)

Volatomics for Diagnosis and Risk Stratification of MASLD: A Proof‐Of‐Concept Study
par: R. Sinha, et autres
Publié: (2025)

Editorial: The Impact of Socioeconomic and Ethnic Factors on Chronic Liver Disease
par: Wah Loong Chan, et autres
Publié: (2024)

Effects of Resmetirom on Metabolic‐Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon‐Like Peptide‐1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO ‐ NASH Trial
par: Mazen Noureddin, et autres
Publié: (2025)

Machine learning improves the prediction of significant fibrosis in Asian patients with metabolic dysfunction‐associated steatotic liver disease – The Gut and Obesity in Asia (GO‐ASIA) Study
par: Nipun Verma, et autres
Publié: (2024)

Head‐to‐Head Comparison Between Phosphatidylethanol Versus Indirect Alcohol Biomarkers for Diagnosis of MetALD Versus MASLD: A Prospective Study
par: Federica Tavaglione, et autres
Publié: (2025)

Global epidemiology of alcohol‐associated liver disease in adolescents and young adults
par: Pojsakorn Danpanichkul, et autres
Publié: (2024)

The impact of genetic risk on the prevalence of advanced fibrosis and cirrhosis in prospectively assessed patients with type 2 diabetes
par: Lana Bridi, et autres
Publié: (2024)

Editorial: Hyperferritinaemia—An Ironclad Biomarker for the Prognostication of MASLD?
par: Mark C. C. Cheah, et autres
Publié: (2025)

Editorial: Cardiometabolic criteria matters inMASLD
par: Margaret L. P. Teng, et autres
Publié: (2024)

Letter on ‘Head‐to‐Head Comparison Between Phosphatidylethanol Versus Indirect Alcohol Biomarkers for Diagnosis of MetALD Versus MASLD: A Prospective Study’
par: Muhammad Abubakr, et autres
Publié: (2025)

Editorial: NAFLD, NAFLD, or MASLD: what's in a name?
par: Maryam Zafer, et autres
Publié: (2024)

CAMP‐B score predicts the risk of hepatocellular carcinoma in patients with chronic hepatitis B after HBsAg seroclearance
par: Hye Won Lee, et autres
Publié: (2024)

Letter: Lubiprostone Treatment for MASLD—Gender Imbalance and Blinding Considerations
par: Jiru Li, et autres
Publié: (2025)

Editorial: Chrononutrition and MASLD—Its About Time (Restricted Feeding)!
par: Hannah Mohr, et autres
Publié: (2025)

Global Longitudinal Assessment of MASLD Using Magnetic Resonance Elastography ( GOLDMINE ): A Multi‐Center, International Prospective Cohort Study of Imaging Biomarkers in MASLD Clinical Outcomes
par: Suzanne Sharpton, et autres
Publié: (2026)

Letter: Lubiprostone—A Novel Therapeutic Avenue for Gastrointestinal Complications in MASLD
par: Hassan Javed, et autres
Publié: (2025)

Letter: Boosting non‐invasive tests—Opportunities and challenges from resmetirom
par: Gong Feng, et autres
Publié: (2024)

Gastrointestinal Cancer Risk in Steatotic Liver Diseases: MASLD , MetALD and ALD
par: Nobuharu Tamaki, et autres
Publié: (2025)

Editorial: Refining the Natural History of MASLD by Imaging‐Based Markers: The GOLDMINE Study
par: Federico Perna, et autres
Publié: (2026)

Editorial: Breath Profiling in MASLD—A Step Towards Better Risk Stratification
par: Takefumi Kimura
Publié: (2025)

Letter: Lubiprostone Treatment for MASLD—Gender Imbalance and Blinding Considerations. Authors' Reply
par: Mohamed El‐Kassas, et autres
Publié: (2025)

Editorial: Polypharmacy in MASLD—An Overlooked Epidemic Disproportionately Affecting Women and Patients With Cirrhosis
par: Mary Yue Wang, et autres
Publié: (2025)

Editorial: Enriching our understanding of MASLD through representation of under‐reported populations
par: Niharika Samala, et autres
Publié: (2024)

Editorial: ABID‐LSM–A Promising Model for Predicting Decompensation Risk in MASLD Cirrhosis
par: Eduardo Vilar‐Gomez, et autres
Publié: (2025)

Letter: Towards Better Intervention Strategies for MASLD and MetALD—What Are We Missing?
par: Qiang Hu, et autres
Publié: (2024)

Prevalence of Low FIB‐4 in MASLD‐Related Hepatocellular Carcinoma: A Multicentre Study
par: Darren Jun Hao Tan, et autres
Publié: (2024)

Letter: A Prospective Study on the Prevalence of MASLD in Patients With Type 2 Diabetes and Hyperferritinaemia
par: Xiaojuan Liu, et autres
Publié: (2025)

Anthropometric Measures and Mortality Risk in Individuals With Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD): A Population‐Based Cohort Study
par: Yee Hui Yeo, et autres
Publié: (2025)

Editorial: Genetics for non‐invasive risk stratification—Finding the needle in the haystack? Authors' reply
par: Lana Bridi, et autres
Publié: (2024)

The Proteomics of MASLD Progression: Insights From Functional Analysis to Drive the Development of New Therapeutic Solutions
par: Carlos José Pirola, et autres
Publié: (2025)

Letter: Algorithmic NIT approaches to identify advanced liver fibrosis in patients with MASLD: Authors' reply
par: Stuart McPherson, et autres
Publié: (2024)

Waitlist and Post‐Transplant Outcomes in Liver Transplantation for Alcohol‐Associated Liver Disease: An Individual Patient Data Meta‐Analysis
par: Glenn Jun Kit Ho, et autres
Publié: (2025)

Letter: Clarifying the Synergistic Mechanisms of Mediterranean Diet and Time‐Restricted Feeding in MASLD Management—Authors' Reply
par: Sofia Tsitsou, et autres
Publié: (2025)

Letter: Towards Better Intervention Strategies for MASLD and MetALD—What Are We Missing? Authors' Reply
par: Yewan Park, et autres
Publié: (2024)